{{product.productLabel}} {{product.model}}
{{#if product.featureValues}}{{product.productPrice.formattedPrice}} {{#if product.productPrice.priceType === "PRICE_RANGE" }} - {{product.productPrice.formattedPriceMax}} {{/if}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
{{product.productLabel}} {{product.model}}
{{#if product.featureValues}}{{product.productPrice.formattedPrice}} {{#if product.productPrice.priceType === "PRICE_RANGE" }} - {{product.productPrice.formattedPriceMax}} {{/if}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
Immunoreaction cartridges to be used with the automated LUMIPULSE G System for the quantitative measurement of β-amyloid1-40 in human plasma. This product is not for use in diagnostic procedures, for ‘Research Use Only.
Fujirebio
... concordant with amyloid PET, and is able to differentiate between Alzheimer's disease and non-Alzheimer's disease neurodegenerative diseases and to predict progression ...
Fujirebio
Immunoreaction cartridges to be used with the automated LUMIPULSE G System for the quantitative measurement of β-amyloid1-42 in human plasma. This product is not for use in diagnostic procedures, for ‘Research Use Only’.
Fujirebio
Immunoreaction cartridges to be used with the automated LUMIPULSE G System for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma. This product is not for use in diagnostic procedures, ...
Fujirebio
Sample volume: 0.025 ml
... CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6). Details Features ...
Fujirebio
Sample volume: 0.075 ml
... CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression. The discrimination ...
Fujirebio
Sample volume: 0.025 ml
... CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6). Details Features ...
Fujirebio
... This assay should be used in combination with the NPTX2 CAL-RVC pack, article no. 80909 (RUO), of the corresponding lot. Test principle The INNOTEST NPTX2 is a solid-phase enzyme immunoassay in which the neuronal ...
Fujirebio
Sample volume: 0.3 ml
... CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression.1-5 The discrimination ...
Fujirebio
Sample volume: 0.075 ml
... CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression.1-5 The discrimination ...
Fujirebio
Please specify:
Help us improve:
remaining